Chinese contract research and manufacturing outfit ChemPartner is building out its U.S. footprint in the heart of the ...

Fosun Pharma has outlicensed a second inflammatory disease candidate to a Western biotech startup right on the heels of a similar deal unveiled earlier this month. | Right on the heels of a similar ...

ProVerum has raised $80 million in venture capital funding to complete the development of its minimally invasive, stent-like implant to relieve the urinary symptoms of an enlarged prostat | The Dublin ...

Abbott has collected a green light in Europe for its dissolving, drug-laden stent in peripheral artery disease, following its ...

Eight months after Sanofi’s former Chief Medical Officer, Dietmar Berger, M.D., departed, the French drugmaker has selected ...

Lineage Cell Therapeutics has found an experienced hearing loss partner to advance a potentially novel transplant for ...

Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.

Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new ...

The National Cancer Institute (NCI) is ending its support for a 26-year-old push to advance clinical trials for children with ...

After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s | ...

Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...

Gumokimab, also called AK111, is an anti-IL-17A monoclonal antibody that Akeso has already tested out in a separate phase 3 ...